Platelet-derived serotonin links vascular disease and tissue fibrosis

Journal of Experimental Medicine

Volumn 208, Issue 5, 2011, Pages 961-972

  Dees, Clara ^a   Akhmetshina, Alfiya ^a   Zerr, Pawel ^a   Reich, Nicole ^a   Palumbo, Katrin ^a   Horn, Angelika ^a   Jüngel, Astrid ^b   Beyer, Christian ^a   Krönke, Gerhard ^a   Zwerina, Jochen ^a   Reiter, Rudolf ^c   Alenina, Natalia ^d   Maroteaux, Luc ^e   Gay, Steffen ^b   Schett, Georg ^a   Distler, Oliver ^b   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Ergonex Pharma GmbH   (Switzerland)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 METHYL 5 ISOTHIAZOLYL)UREA; CLOPIDOGREL; CYPROHEPTADINE; IMATINIB; SEROTONIN; SEROTONIN 2 AGONIST; SEROTONIN 2B RECEPTOR; SMAD PROTEIN; TERGURIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR DISEASE;

ANIMALS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; MICE; MICE, KNOCKOUT; PLATELET ACTIVATION; RECEPTOR, SEROTONIN, 5-HT2B; SCLERODERMA, SYSTEMIC; SEROTONIN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 79956122627     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20101629     Document Type: Article

References (62)

1. Akhmetshina, A., C. Dees, M. Pileckyte, B. Maurer, R. Axmann, A. Jüngel, J. Zwerina, S. Gay, G. Schett, O. Distler, and J.H. Distler. 2008. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22:2214-2222.
2. Andrews, N.C., and D.V. Faller. 1991. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:2499.
3. Ashour, K., L. Shan, J.H. Lee, W. Schlicher, K. Wada, E. Wada, and M.E. Sunday. 2006. Bombesin inhibits alveolarization and promotes pulmonary fibrosis in newborn mice. Am. J. Respir. Crit. Care Med. 173:1377-1385.
4. Bataller, R., and D.A. Brenner. 2005. Liver fibrosis. J. Clin. Invest. 115:209-218.
5. Biondi, M.L., B. Marasini, E. Bianchi, and A. Agostoni. 1988. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Int. J. Cardiol. 19:335-339.
6. Bonhaus, D.W., C. Bach, A. DeSouza, F.H. Salazar, B.D. Matsuoka, P. Zuppan, H.W. Chan, and R.M. Eglen. 1995. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol. 115:622-628.
7. Chung, L., E. Krishnan, and E.F. Chakravarty. 2007. Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology (Oxford). 46:1808-1813.
8. Czuwara-Ladykowska, J., F. Shirasaki, P. Jackers, D.K. Watson, and M. Trojanowska. 2001. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J. Biol. Chem. 276:20839- 20848.
9. Distler, J.H., C. Hagen, A. Hirth, U. Müller-Ladner, H.M. Lorenz, A. del Rosso, B.A. Michel, R.E. Gay, R. Nanagara, K. Nishioka, et al. 2004. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factorkappaB and simian virus 40 promoter factor 1 pathways. Mol. Pharmacol. 65:389-399.
10. Distler, J.H., A. Jüngel, L.C. Huber, C.A. Seemayer, C.F. Reich III, R.E. Gay, B.A. Michel, A. Fontana, S. Gay, D.S. Pisetsky, and O. Distler. 2005. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc. Natl. Acad. Sci. USA. 102:2892-2897.
11. Distler, J.H., A. Jüngel, L.C. Huber, U. Schulze-Horsel, J. Zwerina, R.E. Gay, B.A. Michel, T. Hauser, G. Schett, S. Gay, and O. Distler. 2007a. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56:311-322.
12. Distler, J.H., A. Jüngel, M. Pileckyte, J. Zwerina, B.A. Michel, R.E. Gay, O. Kowal-Bielecka, M. Matucci-Cerinic, G. Schett, H.H. Marti, et al. 2007b. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 56:4203-4215.
13. Distler, O., A. Del Rosso, R. Giacomelli, P. Cipriani, M.L. Conforti, S. Guiducci, R.E. Gay, B.A. Michel, P. Brühlmann, U. Müller-Ladner, et al. 2002. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 4:R11.
14. Fabre, A., J. Marchal-Sommé, S. Marchand-Adam, C. Quesnel, R. Borie, M. Dehoux, C. Ruffié, J. Callebert, J.M. Launay, D. Hénin, et al. 2008.Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur. Respir. J. 32:426-436.
15. Fries, J.F., J.A. Lindgren, and J.M. Bull. 1973. Scleroderma-like lesions and the carcinoid syndrome. Arch. Intern. Med. 131:550-553.
16. Gabrielli, A., E.V. Avvedimento, and T. Krieg. 2009. Scleroderma. N. Engl. J. Med. 360:1989-2003.
17. Glusa, E., and H.H. Pertz. 2000. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br. J. Pharmacol. 130:692-698.
18. Goldberg, S.C., K.A. Halmi, E.D. Eckert, R.C. Casper, and J.M. Davis. 1979. Cyproheptadine in anorexia nervosa. Br. J. Psychiatry. 134:67-70.
19. Green, M.C., H.O. Sweet, and L.E. Bunker. 1976. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am. J. Pathol. 82:493-512.
20. Gustafsson, B.I., K. Tømmerås, I. Nordrum, J.P. Loennechen, A. Brunsvik, E. Solligård, R. Fossmark, I. Bakke, U. Syversen, and H. Waldum. 2005. Long-term serotonin administration induces heart valve disease in rats. Circulation. 111:1517-1522.
21. Hallen, A. 1964. Fibrosis in the carcinoid syndrome. Lancet. 283:746-747.
22. Hervé, P., J.M. Launay, M.L. Scrobohaci, F. Brenot, G. Simonneau, P. Petitpretz, P. Poubeau, J. Cerrina, P. Duroux, and L. Drouet. 1995. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99:249-254.
23. Hofmann, C., U. Penner, R. Dorow, H.H. Pertz, S. Jähnichen, R. Horowski, K.P. Latté, D. Palla, and B. Schurad. 2006. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin. Neuropharmacol. 29:80-86.
24. Humphrey, P.P., P. Hartig, and D. Hoyer. 1993. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol. Sci. 14:233-236.
25. Jähnichen, S., R. Horowski, and H.H. Pertz. 2005. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur. J. Pharmacol. 513:225- 228.
26. Jüngel, A., O. Distler, U. Schulze-Horsel, L.C. Huber, H.R. Ha, B. Simmen, J.R. Kalden, D.S. Pisetsky, S. Gay, and J.H. Distler. 2007. Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis Rheum. 56:3564-3574.
27. Kahaleh, M.B., I. Osborn, and E.C. Leroy. 1982. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann. Intern. Med. 96:610-613.
28. Kasho, M., M. Sakai, T. Sasahara, Y. Anami, T. Matsumura, T. Takemura, H. Matsuda, S. Kobori, and M. Shichiri. 1998. Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int. 54:1083-1092.
29. Katayama, I., and K. Nishioka. 1997. Substance P augments fibrogenic cytokine-induced fibroblast proliferation: possible involvement of neuropeptide in tissue fibrosis. J. Dermatol. Sci. 15:201-206.
30. Khelifi, A.F., M.S. D'Alcontres, and P. Salomoni. 2005. Daxx is required for stress-induced cell death and JNK activation. Cell Death Differ. 12:724- 733.
31. Lawrie, A., E. Spiekerkoetter, E.C. Martinez, N. Ambartsumian, W.J. Sheward, M.R. MacLean, A.J. Harmar, A.M. Schmidt, E. Lukanidin, and M. Rabinovitch. 2005. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ. Res. 97:227-235.
32. LeRoy, E.C., and T.A. Medsger Jr. 2001. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28:1573-1576.
33. MacDonald, R.A., S.L. Robbins, and G.K. Mallory. 1958. Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate. Proc. Soc. Exp. Biol. Med. 97:334-337.
34. Makridis, C., J. Rastad, K. Oberg, and G. Akerström. 1996. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J. Surg. 20:900-906.
35. Mercié, P., M. Seigneur, and C. Conri. 1995. Plasma thrombomodulin as a marker of vascular damage in systemic sclerosis. J. Rheumatol. 22:1440- 1441.
36. Modlin, I.M., M.D. Shapiro, and M. Kidd. 2004. Carcinoid tumors and fibrosis: an association with no explanation. Am. J. Gastroenterol. 99:2466- 2478.
37. Moertel, C.G., W.G. Sauer, M.B. Dockerty, and A.H. Baggenstoss. 1961. Life history of the carcinoid tumor of the small intestine. Cancer. 14:901-912.
38. Moertel, C.G., L.K. Kvols, and J. Rubin. 1991. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer. 67:33-36.
39. Nebigil, C.G., D.S. Choi, A. Dierich, P. Hickel, M. Le Meur, N. Messaddeq, J.M. Launay, and L. Maroteaux. 2000. Serotonin 2B receptor is required for heart development. Proc. Natl. Acad. Sci. USA. 97:9508-9513.
40. Obeso, J.A., J.C. Rothwell, N.P. Quinn, A.E. Lang, J. Artieda, and C.D. Marsden. 1986. Lisuride in the treatment of myoclonus. Adv. Neurol. 43:191-196.
41. Pavlovic, M., P. Saiag, J.P. Lotz, E. Marinho, T. Clerici, and V. Izrael. 1995. Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide. Arch. Dermatol. 131:1207-1209.
42. Postlethwaite, A.E., and T.M. Chiang. 2007. Platelet contributions to the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 19:574-579.
43. Reimund, E. 1987. Methysergide and retroperitoneal fibrosis. Lancet. 392:443.
44. Roth, B.L. 2007. Drugs and valvular heart disease. N. Engl. J. Med. 356:6-9.
45. Rothman, R.B., M.H. Baumann, J.E. Savage, L. Rauser, A. McBride, S.J. Hufeisen, and B.L. Roth. 2000. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 102:2836-2841.
46. Ruddell, R.G., F. Oakley, Z. Hussain, I. Yeung, L.J. Bryan-Lluka, G.A. Ramm, and D.A. Mann. 2006. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am. J. Pathol. 169:861-876.
47. Setola, V., S.J. Hufeisen, K.J. Grande-Allen, I. Vesely, R.A. Glennon, B. Blough, R.B. Rothman, and B.L. Roth. 2003. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy" ) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63:1223-1229.
48. Sgonc, R., M.S. Gruschwitz, H. Dietrich, H. Recheis, M.E. Gershwin, and G. Wick. 1996. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J. Clin. Invest. 98:785-792.
49. Slominski, A., A. Pisarchik, B. Zbytek, D.J. Tobin, S. Kauser, and J. Wortsman. 2003. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J. Cell. Physiol. 196:144-153.
50. Soma, Y., K. Takehara, S. Sato, and Y. Ishibashi. 1993. Increase in plasma thrombomodulin in patients with systemic sclerosis. J. Rheumatol. 20: 1444-1445.
51. Stachów, A., S. Jabłońska, and A. Skiendzielewska. 1979. Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma. Acta Derm. Venereol. 59:1-5.
52. Steen, V.D., and T.A. Medsger. 2007. Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 66:940-944.
53. Strieter, R.M., and B. Mehrad. 2009. New mechanisms of pulmonary fibrosis. Chest. 136:1364-1370.
54. Szegedi, A., and N. Schwertfeger. 2005. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin. Pharmacother. 6:631-641.
55. Varga, J., and D. Abraham. 2007. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117:557-567.
56. von Werner, K., K.-J. Gräf, A. Scholz, and R. Horowski. 1989. Therapy with terguride. Nichidoku-Iho. 33:189-200.
57. Walther, D.J., J.U. Peter, S. Bashammakh, H. Hörtnagl, M. Voits, H. Fink, and M. Bader. 2003a. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 299:76.
58. Walther, D.J., J.U. Peter, S. Winter, M. Höltje, N. Paulmann, M. Grohmann, J. Vowinckel, V. Alamo-Bethencourt, C.S. Wilhelm, G. Ahnert-Hilger, and M. Bader. 2003b. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell. 115:851-862.
59. Wang, S., M.C. Wilkes, E.B. Leof, and R. Hirschberg. 2005. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 19:1-11.
60. Woessner, J.F. Jr. 1961. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 93:440-447.
61. Wouters, M.M., S.J. Gibbons, J.L. Roeder, M. Distad, Y. Ou, P.R. Strege, J.H. Szurszewski, and G. Farrugia. 2007. Exogenous serotonin regulates proliferation of interstitial cells of Cajal in mouse jejunum through 5-HT2B receptors. Gastroenterology. 133:897-906.
62. Zarafonetis, C.J., S.H. Lorber, and S.M. Hanson. 1958. Association of functioning carcinoid syndrome and scleroderma. I. Case report. Am. J. Med. Sci. 236:1-14.